LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Strona główna・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Closed

SectorHealthcare

64.11 -1.61

Buy Sell

Overview

Share price change

24h

Current

Min

63.8

Max

64.69

Key metrics
By Trading Economics
Income	-317M -142M
Sales	98M 452M
P/E Sector Avg	25.027 49.8
Profit margin	-31.342
Employees	423
EBITDA	-3.5M 281M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+40.99% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.7B 7.6B
Previous open	65.72
Previous close	64.11

News Sentiment

By Acuity

44%

56%

128 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

60.49 / 70.14 Support & Resistance

Halozyme Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 maj 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 maj 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 maj 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 maj 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 maj 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 maj 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 maj 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 maj 2026, 10:21 UTC

Earnings

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 maj 2026, 06:05 UTC

Earnings

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 maj 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 maj 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 maj 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 maj 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 maj 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 maj 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 maj 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 maj 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 maj 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 maj 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 maj 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 maj 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 maj 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 maj 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 maj 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 maj 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

40.99% upside

12 Months Forecast

Average 90.4 USD 40.99%

High 96 USD

Low 75 USD

Based on 5 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

60.49 / 70.14Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

128 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.